Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment

Nuvation Bio Inc. (NYSE:NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (NCCN Guidelines) for Non-Small Cell Lung Cancers (NSCLC).

With the addition, Taletrectinib (IBTROZI) is now considered a preferred agent for first-line and subsequent therapy for ROS1-positive NSCLC. It can also be used on brain metastases and resistance mutations.

“These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights preferred utilization of ROS1-targeted agents instead of immunotherapy and chemotherapy for these patients,” said David Hung, M.D., Founder, President, and Chief Executive Officer.

The approval comes on the heels of the US Food and Drug Administration’s approval of Taletrectinib (IBTROZI) as a treatment for adult patients with advanced or metastatic ROS1+ NSCLC in June.

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biotech firm focused on developing specialized cancer treatments for hard-to-treat tumors. Its lead candidate, IBTROZI, is at the forefront of its pipeline.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

Disclosure: None. This article is originally published at Insider Monkey.